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Endothelial xanthine oxidoreductase (XOR) together with NAD(P)H oxidase and nitric oxide (NO) syn-
thase plays a physiologic role in inﬂammatory signalling, the regulation of NO production and vascular
function. The oxidative stress generated by these enzymes may induce endothelial dysfunction, leading
to atherosclerosis, cardiovascular diseases and metabolic syndrome. XOR activity creates both oxidant
and anti-oxidant products that are implicated in the development of hypertension, smoking vascular
injury, dyslipidemia and diabetes, which are the main risk factors of atherosclerosis. In particular, uric
acid may have a protective as well as a detrimental role in vascular alterations, thus justifying the multi-
directional effects of XOR inhibition. Moreover, XOR products are associated with cell differentiation,
leading to adipogenesis and foam cell formation, as well as to the production of monocyte chemo-
attractant protein-1 from arterial smooth muscle cells, after proliferation and migration. The role of XOR
in adipogenesis is also connected with insulin resistance and obesity, two main features of type 2
diabetes.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Contents
1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 562
2. Oxidants-producing endothelial enzymes and atherosclerosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 563
3. Xanthine oxidoreductase activity in hyperuricemia and hypertension . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 563
4. Xanthine oxidoreductase activity in cardiovascular damage by smoking . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 564
5. Xanthine oxidoreductase activity in hypercholesterolaemia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 565
6. Xanthine oxidoreductase activity in obesity and diabetes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 565
7. Role of xanthine oxidoreductase activity in adipogenesis and differentiation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 565
8. Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 566
Funding . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 566
Conflict of interest . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 566
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 566nuclear factor kappa-light-
oxide; PPARg, peroxisome
tive oxygen species; XDH,
R, xanthine oxidoreductase;
.G. Battelli), letizia.polito@
gnesi).
Ireland Ltd. This is an open access1. Introduction
Xanthine oxidoreductase (XOR) is responsible for purine
catabolism, catalysing the oxidation of hypoxanthine to xanthine
and of xanthine to uric acid, which in vivo possesses both anti-
oxidant (primarily in plasma) and pro-oxidant (primarily within
the cell) activities [reviewed in Ref. [1]].article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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xanthine dehydrogenase (XDH, EC 1.1.1.204), which prefers NADþ
as an electron acceptor, and xanthine oxidase (XO, EC 1.1.3.22),
which transfers the electrons directly tomolecular oxygen, with the
production of the reactive oxygen species (ROS) superoxide anion
and hydrogen peroxide. The production rate of these two ROS de-
pends on O2 tension, pH and purine concentration, the formation of
hydrogen peroxide being favoured when O2 levels and pH are
reduced as under ischaemic and/or hypoxic conditions [reviewed in
Ref. [3]].
XOR is a molybdo-ﬂavo homodimer that consists of two iden-
tical subunits of approximately 145 kDa, each containing two iron
sulphur centres. The conversion from XDH to XO may occur
through the oxidation of sulfhydryl residues or limited proteolysis
[reviewed in Ref. [4]]. Thus, XOR activity generates both oxidant
and anti-oxidant products.
XOR is constitutively expressed in the dehydrogenase form,
primarily by epithelial cells in the liver, intestine and mammary
gland; XOR serum levels are usually very low in humans. However,
XOR levels may become more elevated in some pathological con-
ditions, which cause XOR release from damaged cells into the cir-
culation, where it is converted to the oxidase form. Circulating XOR
may bind to endothelial cells, where it is responsible for remote
organ injury and has been implicated in the development of
endothelial dysfunction. In a recent review, the experimental and
clinical pathologies leading to increased serum level of XOR were
exhaustively discussed, and the vascular effects of oxidants pro-
duced by circulating enzymes and their role in cardiovascular dis-
eases were addressed [reviewed in Ref. [5]]. The present review
focus on the role of XOR in the endothelial dysfunction that is
central to atherosclerosis.Fig. 1. Regulation of nitrogen oxide (NO) production by endothelial enzymes. NO
may be produced by NO synthase activity and also through the reduction of nitrite by
NAD(P)H and xanthine oxidoreductase (XOR) activities. NAD(P)H oxidase and XOR may
activate each other through the production of superoxide anion, whereas NO synthase
and XOR may inhibit each other through their products [reviewed in Ref. [8]].2. Oxidants-producing endothelial enzymes and
atherosclerosis
The investigation of oxidative stress has generated a large body
of evidence underlining its implications in cytotoxicity and tissue
injury. Today, ROS are receiving growing consideration for their
physiologic roles in inﬂammatory signalling and the regulation of
vascular function. In both cases, these oxidants are produced in
endothelial cells largely by NAD(P)H oxidase, nitric oxide (NO)
synthase, and XOR. The dysregulation of these enzymes is associ-
ated with impaired vascular function and cardiovascular diseases
[reviewed in Ref. [6]]. The role of these enzymes in the cardio-
protection secondary to nitrite administration was investigated in
a rat model of myocardial ischemia/reperfusion injury [7]. Infarc-
tion was associated with an increase in myocardial XOR activity.
The protective effect of nitrite was dependent on the drug dose and
was abolished by the inhibition of NAD(P)H oxidase or XOR activ-
ities, although it was unaffected by the inhibition of NO synthase.
These results indicate that ischaemic conditions abolish NO syn-
thase activity and that the generation of NO from the reduction of
nitrite is the result of the activities of NAD(P)H oxidase and XOR. In
these conditions, the inhibition of XOR activity with allopurinol
may abolish the salutary outcomes due to nitrite treatment
[reviewed in Ref. [3]].
Moreover, XOR-derived ROS may activate NAD(P)H oxidase ac-
tivity and vice versa; thus, the roles of these two enzymes in car-
diovascular diseases are strictly interrelated [reviewed in Ref. [8]].
Furthermore, XOR activity is inhibited by NO or by reactive nitrogen
species that may originate from the reaction between XOR-derived
superoxide and NO; however, on the other hand, XOR-derived ROS
can inhibit NO synthase activity. Thus, enhanced NO production
may occur in response to XOR inhibition in vivo [reviewed in Ref.[9]]. The interplay between endothelial NAD(P)H oxidase, NO
synthase and XOR activities is presented in Fig. 1.
The pro-inﬂammatory action of XOR products has been shown
to be relevant to pathologies resulting from vascular dysfunction.
Oxidants produced by endothelium-bound XOR have been impli-
cated in the pathogenesis of atherosclerosis by a variety of studies
[reviewed in Ref. [10]]. In atherosclerotic plaques from patients
who underwent carotid endarterectomy, the accumulation of uric
acid and XOR, which were more concentrated in endothelium and
smooth muscle cells and were co-localised with cholesterol, was
identiﬁed using an immune-staining based test [11].
Bovine aortic endothelial cells exposed to oscillatory shear
stress exhibit enhanced superoxide production that is associated
with an elevated ratio of XO to XDH. The addition of oxypurinol or
tungsten to endothelial cell cultures inhibited this superoxide
production, suggesting that the mechanical stress exerted by blood
ﬂowing over the endothelium induces oxidative stress through the
conversion of XOR to its ROS-generating form, thus indicating a link
between XOR activity and the pathogenesis of atherosclerosis [12].
Recently, the effects of XOR activity inhibition by treatment with
allopurinol or febuxostat have been compared to analyse the pro-
tection given in heart failure, chronic kidney diseases, and other
pathologies [reviewed in Ref. [13]]. In a mouse model, febuxostat
provided protection by attenuating systolic overload-induced left
ventricular hypertrophy and dysfunction [14]. In rats with fructose-
induced metabolic syndrome, febuxostat was able to correct hy-
peruricemia, hypertension, and hypertriglyceridemia. Moreover,
this treatment prevented the increase in fasting plasma insulin [15].
However, XOR inhibition may lead to clinical improvement as well
as to opposite results in cardiovascular diseases depending on the
level of serum uric acid [reviewed in Ref. [16]].
The main risk factors of atherosclerosis, i.e., hypertension,
smoking, dyslipidemia, and diabetes, may trigger the pathogenesis
of endothelial dysfunction at least in part through XOR-induced
oxidative stress (Fig. 2). As a consequence of this ROS-driven
vascular dysfunction, loss of vasodilatation, inﬂammation and
platelet aggregationmay be elicited, thus promoting cardiovascular
diseases [reviewed in Ref. [17]].
3. Xanthine oxidoreductase activity in hyperuricemia and
hypertension
XOR activity in the myocardial tissue of spontaneously hyper-
tensive rats was higher than in controls [18]. An increase in oxy-
radicals production has been reported in the microvascular
endothelium of spontaneously hypertensive rats, which coincided
with the elevated arteriolar tone compared with control animals.
Fig. 2. Role of xanthine oxidoreductase (XOR) in atherosclerosis pathogenesis.
Increased endothelium-associated XOR activity contributes to the pathogenesis of
vascular oxidative stress and inﬂammatory responses related to smoke damage, hy-
pertension, diabetes, and hypercholesterolaemia [reviewed in Ref. [10]]. ROS: reactive
oxygen species; UAFR: uric acid-derived free radicals.
Fig. 3. Arteriolar effects of uric acid-derived free radicals (UAFR). Impaired vaso-
dilatation may be caused by UAFR, which induce the up-regulation of the renin/
angiotensin pathway and decrease nitric oxide (NO) availability. Furthermore, UAFR
may activate smooth muscle cells (SMC) by inducing the migration, proliferation, and
production of monocyte chemotactic protein-1 (MCP-1) [reviewed in Ref. [28]]. XOR,
xanthine oxidoreductase; eNOs, endothelial nitric oxide synthase.
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of XOR, or chemical inhibition of XOR activity prevented ROS over-
production and the elevation of blood pressure and arteriolar tone
[19].
The involvement of XOR-derived oxidants in the pathogenesis of
salt-induced hypertension was indicated by the lowering of blood
pressure and the reduction of ROS production in the endothelium
of arterioles and venules of salt-sensitive rats after pre-treatment
with tungsten [20]. Additionally, renal XOR activity was higher in
spontaneously hypertensive rats than in control rats, and blood
pressure was increased in both groups by a high-salt diet. Hyper-
tension was correlated to renal XOR activity and to induced left
ventricular and renal hypertrophy, which were prevented by allo-
purinol treatment [20].
The XOR activity was shown to be a regulator of cyclooxygenase-
2 (COX-2) expression in studies with XOR null mice [21]. Moreover,
the expression of COX-2 can be stimulate by uric acid in vitro and
in vivo providing a link between elevated serum uric levels and
inﬂammatory response, suggesting a correlation of hyperuricemia
with systemic hypertension. However, the inhibition of XOR by
allopurinol or febuxostat did not alter the progression of high blood
pressure in deoxycorticosterone acetate-salt treated rats [22]. The
results obtained in this animal model of hypertension suggest that
a causeeeffect relationship could not be established between hy-
peruricemia and hypertension.
The elevation of systolic blood pressure in ageing rats, which
was associated with increased ROS production, appeared to be
dependent on the vascular activity of XOR, not on NAD(P)H oxidase
activity [23]. On the other hand, XOR inhibition by allopurinol
treatment abolished the nitrite-induced dose-dependent blood
pressure-lowering effects in spontaneously hypertensive rats,
possibly because of the simultaneous inhibition of XOR-dependent
nitrite reductase activity localised to the erythrocyte, whereas no
effect was observed on the reduction of nitrite at the blood vessel
wall [24].In a comparative study, two groups of patients with similar
increased cardiovascular risks but differing in the presence/absence
of hyperuricemia were observed. Hyperuricemic patients exhibited
impaired ﬂow-mediated vasodilatation that was reversed to the
level of controls through XOR inhibition by allopurinol treatment
[25]. Allopurinol ameliorated endothelial function and reduced
oxidative stress by inhibiting XOR and decreasing myeloperoxidase
levels in patients with metabolic syndrome [26]. Also, an
improvement of endothelial function and artery ﬂow together with
a decrease in circulating uric acid and markers of oxidative stress
has been reported in a meta-analysis study investigating the out-
comes of XOR activity inhibition in patients with, or at risk of,
cardiovascular disease [reviewed in Ref. [27]].
Many experimental data indicate that a high level of serum uric
acid is an independent risk factor for cardiovascular disease and is
predictive of mortality if associatedwith diabetes and hypertension
in metabolic syndrome. Indeed, this molecule is not inert and gives
rise to free radicals by interacting with superoxide anion, NO,
peroxynitrite and myeloperoxidase. Uric acid-derived free radicals
may cause endothelial dysfunction and vasoconstriction by
lowering NO availability and by stimulating the up-regulation of
the renin/angiotensin pathway (Fig. 3). Also, these free radicals may
induce the migration, proliferation, and production of monocyte
chemotactic protein-1 by arteriolar smooth muscle cells [reviewed
in Ref. [28]], at least in part mediated by uric acideinduced COX-2
expression [reviewed in Ref. [29]].
However, the epidemiological evidence that supports the role of
uric acid as a marker of hypertension is thus far suggestive but
inconclusive to conﬁrm the usefulness of uric acid-lowering ther-
apy in cardiovascular diseases and metabolic syndrome [reviewed
in Ref. [30]].
4. Xanthine oxidoreductase activity in cardiovascular damage
by smoking
XOR activity could be one of the links between cigarette
smoking and cardiovascular diseases. The up-regulation of XOR by
M.G. Battelli et al. / Atherosclerosis 237 (2014) 562e567 565tobacco smoke condensate has been reported in cultured rat pul-
monary endothelial cells after both acute (1 day) and chronic (7
days) exposures through an increase of XOR mRNA expression and
XOR gene promoter activity [31]. Cigarette smoke exposure in
hamsters elicits an early rise in XOR activity, followed by leukocyte
adhesion to the endothelium of arterioles and post-capillary ve-
nules. Both responses are attenuated by ROS scavenging treatment,
suggesting the implication of XOR in the pathogenesis of smoke-
induced vascular alterations [32].
Increased pulmonary XOR activity and protein levels have been
reported inmice exposed to cigarette smoke. Similar increased XOR
expression was obtained in cultured pulmonary human lung
microvascular endothelial cells after exposure to cigarette smoke
extract. XOR activation and the consequent ROS production resul-
ted in DNA double-strand break formation, which mediated the
induction of endothelial cell apoptosis. Cell pre-treatment with
allopurinol or febuxostat demonstrated that DNA damage was
dependent on XOR activity, thus establishing a role for XOR in
cigarette smoking-induced endothelial cell injury [33].
Allopurinol reversed the alteration of vessel resistance induced
by smoking in subjects with no other risk factors for atheroscle-
rosis, suggesting that XOR contributes to endothelial dysfunction
caused by cigarette smoking [34,35].
5. Xanthine oxidoreductase activity in hypercholesterolaemia
Increased superoxide production by endothelial cells has been
reported in diet-induced hypercholesterolemic rabbits, possibly
due to XOR activity [36]. Accordingly, XOR activity inhibition
decreased the superoxide production in aortic rings from hyper-
cholesterolemic [36e38] or diabetic rabbits [39]. The increased
XOR concentration in the plasma of hypercholesterolemic rabbits
suggested a role for XOR in vascular dysfunction [38].
The vascular responses to infusion of an endothelium-
dependent vasodilator and a direct smooth muscle dilator were
studied in hypercholesterolemic and essential hypertensive pa-
tients. XOR inhibition with oxypurinol improved endothelial
vasodilator function in hypercholesterolemic patients but not in
hypertensive patients, suggesting that enzyme-generated ROS are
partly responsible for the impaired vascular response of hyper-
cholesterolemic patients, whereas ROS do not appear to play a
signiﬁcant role in essential hypertension [40]. Increased NAD(P)H
oxidase and XOR activity has been reported in the coronary arteries
of patients with coronary artery disease with respect to impaired
vasodilatory response [41]. The early increase of vascular XOR ac-
tivity has been described in asymptomatic young individuals with
familial hypercholesterolaemia [42].
The role of XOR in atherosclerosis development was studied
together with the effects of the XOR inhibitor allopurinol on this
process in an ApoE knockout mouse model and in a murine
macrophage cell line [43]. In vivo, the treatment with allopurinol
lowered lipid accumulation and calciﬁcation in arteries. The inhi-
bition of XOR activity or knockdown of XOR suppressed the in vitro
transformation of macrophage cells into foam cells after treatment
with lipoproteins, whereas the over-expression of XOR promoted
this transformation.
6. Xanthine oxidoreductase activity in obesity and diabetes
The adipocytes of perivascular adipose tissue have been pro-
posed to contribute to the pathogenesis of atherosclerosis through
their ability to transduce signals to adjacent blood vessels, in
particular modulating inﬂammation, vasoreactivity, and smooth
muscle cell proliferation [reviewed in Ref. [44]]. The regulatory
function of adipocytes that is most relevant to this review includestheir sensitivity to insulin and the production of cytokines, which
inﬂuence energy homoeostasis and metabolism in other tissues
[45].
In rats, a high-fat diet induces an increase in body weight and in
mean arterial blood pressure and elevated serum levels of insulin,
cholesterol, and glucose. In obese rats, increased XOR expression
was detected by immunostaining in the arteriolar endothelium.
Moreover, the arterioles exhibited impaired responses to vaso-
motor stimulus, which was reversed by the inhibition of XOR but
not of NAD(P)H oxidase activity. Additionally, increased superoxide
production, associated with increased XOR, but not NAD(P)H oxi-
dase activity was observed in rat carotid arteries, suggesting that
XOR-derived superoxide production may increase peripheral
resistance via altered arteriolar tone in high-fat diet-induced
obesity [46].
Treatment with allopurinol decreases haemoglobin glycation,
glutathione oxidation, and lipid peroxidation in type 1 diabetic
patients, suggesting a role for XOR inhibition in the prevention of
vascular oxidative stress and complications of diabetes [39]. Pro-
longed treatment with allopurinol normalised endothelial
dysfunction in type 2 diabetic patients with mild hypertension
compared with matched controls. Both groups received intra-
arterial infusions of endothelium-dependent and endothelium-
independent vasodilators, and forearm blood ﬂow responses
were measured after bilateral venous occlusion [47]. Moreover,
XOR activity was implicated in the pathogenesis of diabetes con-
sequences because treatment with metformin signiﬁcantly
decreased serum XOR activity and molecular markers of oxidative
stress in diabetic patients [48].
Increased plasma XOR activity was signiﬁcantly correlated to
NF-kB activation and high levels of inﬂammatory markers and in-
sulin resistance in familial combined hyperlipaemia [49]. The hy-
pothesis has been formulated that an imbalance in both oxidative
stress and oxidative deﬁciency could lead to insulin resistance [50].
Also, increased plasma XOR activity has been reported in associa-
tion with a single exercise session in patients with metabolic syn-
drome as compared to control subjects, suggesting the involvement
of XOR in the pathogenesis of metabolic syndrome [51].
XOR-derived ROS have been proposed amongst the main actors
in the interaction between oxidative and nitrosative/nitrative
stress, that may promote inﬂammation and may lead to myocardial
dysfunction and diabetic cardiomyopathy [reviewed in Ref. [52]].
7. Role of xanthine oxidoreductase activity in adipogenesis
and differentiation
XOR expression signiﬁcantly increased in ﬁbroblastic-like 3T3-
L1 pre-adipocytes at an early time frame during the commitment
to differentiate into a mature adipocyte. Shortly after, increased
XOR activity levels were detected, primarily in the dehydrogenase
form, whereas the level of the oxidase form was unchanged. XOR
mRNA levels correlated in vivo with adipose mass: obese ob/ob
mice exhibited a high enzyme level, which decreased after treat-
ment with leptin, and XOR null mice exhibited decreased adiposity
[53]. In XOR knockout 3T3-L1 cells, reduced lipid accumulationwas
observed in relation with the extent of the inhibition of adipocyte
differentiation. Adipogenesis appeared to be dependent on the
activation of the transcription factor PPARg by the NADH-oxidizing
activity of XOR [53].
These results are consistent with previous ﬁndings regarding
defective fat-droplet secretion in XOR knockout mice, suggesting a
role for XOR in the production and exportation of milk-fat globules
during lactation [54]. Moreover, XOR gene knockout mice exhibited
renal tubule injury with an accumulation of triglycerides that was
possibly related to an increased expression of adipogenesis genes
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lialemesenchymal transition associated with interstitial ﬁbrosis
[55], supporting the existence of a maturation/differentiating
function associated with the XOR gene and with the production of
oxygen radicals or hydrogen peroxide [reviewed in Ref. [56]], which
is in agreement with the reported low XOR expression levels in
anaplastic cancer cells [reviewed in Ref. [57]].
Despite the differences between the purine metabolism of
humans and mice, these ﬁndings suggest a role for XOR in the
regulation of adipogenesis. The pharmacologic activation of PPARg
by bezaﬁbrate may improve insulin sensitivity by up-regulating
adipogenesis, thus decreasing free fatty acid levels and reversing
insulin resistance. For this reason, the therapeutic use of bezaﬁ-
brate has been suggested in patients with atherogenic dyslipidemia
and/or metabolic syndrome to reduce the risk of cardiovascular
events and to delay the onset of type 2 diabetes mellitus [reviewed
in Ref. [58]].
The physiological and pathological roles of XOR in adipogenesis
and differentiation are presented in Fig. 4.
8. Conclusions
This study overviews the role of XOR as a systemic modulator of
redox equilibrium by giving rise to both oxidant and anti-oxidant
products. This function is performed by endothelial cell-bound
XOR together with NAD(P)H oxidase and NO synthase activity.
These enzymes play a physiologic role in the inﬂammatory sig-
nalling and regulation of vascular function, to which XOR contrib-
utes directly through the generation of ROS and uric acid and also
indirectly with uric acid-derived free radicals. Additionally, XOR
products are associated with cell differentiation, leading to adipo-
genesis in different experimental and clinical settings, as well as to
the production of monocyte chemoattractant protein-1 from arte-
rial smooth muscle cells after proliferation and migration. The data
collected and analysed here indicate that XOR activity is associated
with hypertension, cigarette smoking, dyslipidemia and diabetes
and could play a role in the pathogenesis of endothelium damage
induced by the main risk factors for atherosclerosis. Although, no
conclusive results have been obtained thus far, evidence is growing
regarding the beneﬁcial effects of lowering the serum level of uric
acid in metabolic syndrome. The interconnection between XOR,Fig. 4. Roles of xanthine oxidoreductase (XOR) in differentiation and adipogenesis.
Experimental studies demonstrate that XOR activity has physiological functions in
promoting differentiation and adipogenesis [53e55] as well as pathological effects by
inducing the transformation of macrophages to foam cells [43] and fat over-
accumulation [53].NAD(P)H oxidase and NO synthase activities may justify the vari-
able results obtained in clinical trials utilizing XOR inhibitors and
suggests the opportunity of taking in consideration the cross-talk
between these enzymes in designing future experimentations.
The knowledge of the intricate interplay of oxidative/nitrosative
stress with inﬂammation is essential to the understanding of
atherosclerosis pathogenesis and is crucial to develop novel tar-
geted therapies for metabolic syndrome.Funding
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